Acknowledgments
polyp, NINDS, Cancer
CANCER, BROWN
This project (NIHR128210) was funded by the Efficacy and Mechanism Evaluation (EME) Programme, an MRC and NIHR partnership (to C.J. Rees, L.C. Brown, P.M. Loadman, E.A. Williams, M.A. Hull). Microfluidic array design was supported by the European Union-Biotechnology and Biological Sciences Research Council (UK)-funded Fatty Acid Metabolism (FAME) Consortium - Interlinking Diet with Cardio-metabolic Health (BB/P028233/1; R.N.M. Saleh and A.M. Minihane). M.A. Hull and C.J. Rees are NIHR Senior Investigators. A. Downing and M.A. Hull are supported by Cancer Research UK grant C23434/A24939. The Genotype-Tissue Expression (GTEx) Project was supported by the Common Fund of the Office of the Director of the National Institutes of Health, and by NCI, NHGRI, NHLBI, NIDA, NIMH, and NINDS. Data were accessed from the GTEx Portal on 08/17/2023. The Authors wish to thank all the participants and research staff who contributed to the seAFOod polyp prevention trial. The Authors express their gratitude to Professors Tim Bishop and David Westhead for helpful review and advice. Professor Matthias Schulze provided useful advice about candidate SNPs. The Authors also acknowledge the significant contribution of Mr. John Whelpton acting as the Patient & Public representative in the STOP-ADENOMA Study Group.The publication costs of this article were defrayed in part by the payment of publication fees. Therefore, and solely to indicate this fact, this article is hereby marked “advertisement” in accordance with 18 USC section 1734.
